Core Viewpoint - The article highlights the significant weight loss journeys of comedians Rosie O'Donnell and Jim Gaffigan, both of whom have utilized the medication Tirzepatide (brand name Mounjaro) for weight management and diabetes treatment, showcasing the drug's effectiveness and the lifestyle changes accompanying its use [2][4][9]. Group 1: Rosie O'Donnell's Weight Loss Journey - Rosie O'Donnell, at 63, has publicly shared her weight loss journey, attributing her transformation to medication and lifestyle changes, resulting in a slimmer physique [2]. - O'Donnell revealed that she has lost weight while using Tirzepatide for diabetes treatment, which has the side effect of weight loss, and she has also made significant dietary changes, including hiring a personal chef [4][6]. - After a heart attack in 2012 and subsequent gastric sleeve surgery in 2013, O'Donnell's weight decreased from 240 pounds to 176 pounds, and she now wears a size large instead of XL or XXL [4][6]. Group 2: Jim Gaffigan's Weight Loss Journey - Jim Gaffigan, who struggled with weight fluctuations, decided to try medication after reaching 270 pounds, resulting in a weight loss of 50 pounds [7][9]. - Gaffigan expressed gratitude for the positive changes in his life due to the weight loss and the effectiveness of Tirzepatide, which he initially approached with skepticism [9][10]. - He has maintained his health through walking in New York City and has not yet decided how long he will continue the medication, indicating a shift towards a healthier lifestyle [13]. Group 3: Tirzepatide Overview - Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for treating type 2 diabetes and aiding weight loss, with significant clinical trial results showing an average weight loss of 50.3 pounds among participants [9]. - The drug received FDA approval in May 2022 for diabetes management and again in November 2023 for weight management in adults [9].